Skip to content
drillr.ai

CGTX

Cognition Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$0.95-1.27%

Price as of Jul 20, 2026

CGTX news

Cognition Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

    - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=myr-A8wDUp_CSay8fWDF0vDaetevyo4RWMyQbLRx3sNrO_roHuC1PTUO9TMwCNTFeftFQDyDpKjphTYjcfd0ohlDFjieqnFEDJ8Fj8s_LaFyYU1bQjHrgp1c6HwaNVYu), (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developi

    Globe Newswire ·

  2. Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

    PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=0MTCmC400jKiF1VLBfMPjcbcnDgE7hkOGfTo5JlerZ3NAvBmsjuoELxQoh9L_imMVDjExSlzyCFEZ4LuCjmYEtZRNx5x3YAeoPmQh5crVX8pXuigxszVzfmkgs_Kvfbv) (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi (https://www.globenewswire.com/Tracker?data=FNtVivSmTJbhrbHg9KYNLLiKkGL2UlWpsMXwiLdBv

    Globe Newswire ·

  3. Cognition Therapeutics CEO Issues Letter to Shareholders

    Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=bv5DLos7-VO4xg44xXidGc3Doul3LPGuPdT9JBid5KHC3f_MtUiFir4wHNJDutHVK7gtQhyYZXnR9Kw6lJjqZV7L3yN8UKSkiSb_oB1V7Sr-vbSeZ2Rhr7bX-JEyM3UM) (Nasdaq: CGTX), a clinical-stage neuroscience company

    Globe Newswire ·

  4. Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=-k9QSUpvUYZAgsN_aUPTEpJEQc2Is8DZXQcwR3eMeT21Z8jgBdqqmpODOOPARVZe7eCguCGTZM-_q8Q1h-VhMsJK7L2K3fUUex2iWk-DjxY=) (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neu

    Globe Newswire ·

  5. Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

    PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=PTjnG8suDio-y0nYC_JvePCPy0l29xG-k4ZPuzsRtRgVyJ_WiKi7_8YYZ2355lDpAjFrf9x3RLp15ZqGqf0j95Z32IyE1TtIzrs9sQxakaM=) (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026

    Globe Newswire ·